LXRX - Lexicon highlights potential of diabetes drug in heart failure and blood glucose control

Lexicon Pharmaceuticals (NASDAQ:LXRX) is trading ~11.8% higher in the pre-market after announcing a new analysis demonstrating the clinical benefits of diabetes therapy sotagliflozin in heart failure and blood glucose control. The pooled analysis was based on data from SOLOIST and SCORED trials that involved over 11,000 patients with diabetes and heart failure or cardiovascular risk factors. According to a presentation conducted at virtual American Heart Association Scientific Sessions 2021, sotagliflozin has led to a significant reduction in “total cardiovascular deaths, hospitalizations for heart failure, and urgent visits for heart failure across the full range of kidney function studied.” Sotagliflozin is currently approved in Europe as an adjunct to insulin therapy for adults with type 1 diabetes. In 2019, Lexicon (LXRX) suffered a setback when FDA declined to approve sotagliflozin for the indication.

For further details see:

Lexicon highlights potential of diabetes drug in heart failure and blood glucose control